which later became a part of the Bristol-Myers Squibb Pharmaceutical Research Institute. During this time (1985-1997), he developed the first recombinant virus as a candidate HIV vaccine for FDA-approved clinical trials and provided the first demonstration of vaccine protection against SIV infection in a macaque model by the “poxvirus prime-protein boost” immunization strategy.
Courses Taught
Pharmaceutics 533: Biopharmaceutics and Drug Delivery
gp120 and gp160 by S.L. Hu (University of Washington)